AzTrials
AzTrials

Metabolic DisturbanceMsFITNCT06345937

Multiple Risk Factor Intervention Trial (Ms. FIT)

A study testing Behavioural Experimental: guidelines-based physical activity, Behavioural Experimental: guidelines-based physical activity and healthy eating and Behavioural: Stretching exercise in people with Metabolic Disturbance and Sedentary Behavior, run by University of Toronto at 1 site in Canada.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study aims to produce new evidence, specific to women, on the efficacy and mechanisms of exercise and diet for cardiometabolic risk reduction in pre and postmenopausal women. Read more about this study

Who is it for?
Ages 30 years and older, women only
Conditions the study is for
Metabolic Disturbance, Sedentary Behavior
What is being tested?
Behavioural Experimental: guidelines-based physical activity, Behavioural Experimental: guidelines-based physical activity and healthy eating and Behavioural: Stretching exercise
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
180 participants
Where
1 siteCanada
Study dates
3 May 2024to 1 Aug 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Biologically female
  • Aged 30+
  • Pre- or postmenopausal: Premenopause: having regular menstrual cycles (21-35 days long without a persistent difference of ≥7 days between cycles). Post-menopause: ≥12 months of amenorrhea or history of double oophorectomy and do not have irregular or occasional menstrual cycle in last 12 months.
  • Participants will have multiple risk factors for cardiometabolic disease, namely: being sedentary (<30 min of moderate-vigorous physical activity/week), having a BMI ≥ 25 kg/m^2, and one or more of the following: a waist circumference indicative of abdominal obesity, specific to BMI (e.g., BMI 25-29.9: WC: ≥90cm; BMI 30-34.9: WC: ≥105cm; BMI 35-35.9: WC: ≥115cm) OR a diagnosis of either hypertension, pre-diabetes (heightened blood sugar levels), or dyslipidemia (heightened blood lipid levels)
  • Able to commit to come to the University once per week for 24 weeks.

Who cannot join

  • Perimenopausal or those whom the investigators cannot discern pre- vs perimenopausal status
  • Diagnosed cardiovascular diseases, type 2 diabetes, non-alcoholic fatty liver disease, cancer (except for non-melanoma skin cancer), or respiratory disease (e.g., Chronic obstructive pulmonary disease (COPD) or severe or uncontrolled asthma).
  • Major signs or symptoms of cardiovascular diseases, diabetes, or renal disease (taken from the American College of Sports Medicine's Guidelines for Exercise Testing and Prescription 11th edition Table 2.1: pain or discomfort in the chest, neck, jaw, arms with rest or exercise, shortness of breath at rest or with mild exertion, dizziness or syncope, loss of balance or passing out, ankle edema, palpitations or tachycardia, intermittent claudication, known heart murmur, unusual fatigue with usual activities.)
  • American Heart Association's absolute or relative contraindications for symptom-limited maximal exercise testing (myocardial infarction, aortic or coronary artery stenosis, heart failure, pulmonary embolism or deep vein thrombosis, inflammation of the heart (myocarditis, pericarditis, and/or endocarditis), uncontrolled cardiac arrythmia, advanced or complete electrical heart block, stroke or transient ischemia attack, blood pressure >200mmHg/100mmHg, a cancer diagnosis other than skin cancer)
  • Unable to provide informed consent or communicate in English
  • Pregnant or breast-feeding currently or in the past 3 months
Show all 20Show fewer
  • Mobility limitations to aerobic exercise (i.e., wheelchair, walker use, limp impeding walking)
  • Smoking cigarettes or marijuana within the past 3 months
  • Taking exogenous hormones in any format currently or in the past 3 months
  • Contraindications to research MRI (e.g., pacemaker, magnetic implants)
  • BMI exceeding 40 kg/m2
  • Extreme claustrophobia
  • Self-report >30 min/week of moderate-to-vigorous intensity aerobic physical activity
  • Following a diet that largely restricts entire food groups or time of eating (e.g., vegan, ketogenic, carnivore, one meal a day) in last 3 months
  • Students in classes or labs of the professors who are involved in the study
  • Experienced significant weight loss (i.e., >5 kg) in past 3 months
  • Currently taking weight loss medications
  • Diagnosed history of an eating disorder or self-report of potential undiagnosed eating disorder
  • Plans to be away/unavailable for a substantial period of the intervention overall (i.e., >4 weeks throughout the 6 months or >2 weeks within the first 12 weeks of the intervention).
  • Allergies to local anesthetics

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Amy A. Kirkham, PhD contact

416-946-4069

amy.kirkham@utoronto.ca

Jenna B. Gillen, PhD contact

416-978-3244

jenna.gillen@utoronto.ca

Canada1 site, 1 recruiting
  • University of Toronto

    Toronto, Ontario, M5S 2C9

    Amy A. Kirkham, PhD, 416-946-4069, amy.kirkham@utoronto.ca

    Jenna B. Gillen, PhD, 416-978-3244, jenna.gillen@utoronto.ca

    Recruiting

Other trials in Canada

About this study

This study aims to produce new evidence, specific to women, on the efficacy and mechanisms of exercise and diet for cardiometabolic risk reduction in pre and postmenopausal women. Using a 3-arm randomized controlled trial (RCT) with equal recruitment and stratification by menopausal status to 6 months of: 1) exercise following Health Canada guidelines; 2) the same exercise plus counselling to follow Canada's Dietary Guidelines to improve diet quality; or 3) stretching group, this study will answer the following questions:

  • How does the impact of exercise compare among each of the causal links between physical inactivity and cardiometabolic disease in women?
  • What is the effect modification of adding a diet quality intervention to exercise?
  • What is the effect modification by menopausal status?

The investigators hypothesize that exercise adaptations will be: 1) largest peripherally, including Matsuda index (primary outcome), Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), arteriovenous oxygen difference (avO2diff), and visceral fat, compared to centrally (stroke volume (SV), endothelial function, aortic stiffness), 2) blunted or absent in post vs premenopause; 3) enhanced by the addition of diet quality which will be essential or additive for Matsuda index, metabolic syndrome, Framingham cardiovascular disease (CVD) risk, cytokines and adipokines, thigh myosteatosis, muscle mass, peak oxygen uptake (VO2peak), 4) enhanced by adding diet quality in more outcomes postmenopause.

Being tested
Behavioural Experimental: guidelines-based physical activity, Behavioural Experimental: guidelines-based physical activity and healthy eating, Behavioural: Stretching exercise
Keywords
Primary Prevention
Medical subject headings
Sedentary Behavior

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Behavioural Experimental: guidelines-based physical activityBehavioural

    Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.

  • Behavioural Experimental: guidelines-based physical activity and healthy eatingBehavioural

    Behavioural Experimental: guidelines-based physical activity:

    Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.

    Behavioural Experimental: guidelines-based healthy eating:

    One-on-one phone/virtual counselling from a registered dietitian to change dietary habits to be in line with Canada's Food Guide.

  • Behavioural: Stretching exerciseBehavioural

    Twice weekly virtual instructor-led whole-body stretching.

Study groups in NCT06345937
Study groupRoleWhat they receive
Guidelines-based physical activityExperimental150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening
Receives: Behavioral: Behavioural Experimental: guidelines-based physical activity
Guidelines-based physical activity and healthy eatingExperimental150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening + counselling to follow Canada's Food Guide
Receives: Behavioral: Behavioural Experimental: guidelines-based physical activity and healthy eating
Stretching exercisePlacebo comparatorWhole-body stretching
Receives: Behavioral: Behavioural: Stretching exercise

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Insulin resistance

    As assessed by the Matsuda Index calculated from an oral glucose tolerance test (OGTT).

    Measured: 6 months

Secondary outcomes (3)
  1. Hepatic insulin resistance

    Indirectly measured via HOMA-IR using fasting glucose and insulin levels

    Measured: 6 months

  2. Metabolic syndrome severity

    Calculated as a z-score to allow for tracking change in the interventions

    Measured: 6 months

  3. Framingham 10-year risk (%)

    Calculated using a widely-used standardized scoring system

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Apr 2024
  2. Study start3 May 2024
  3. Primary completion1 Aug 2027 (estimated)
  4. Study completion1 Aug 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
3-arm parallel-group randomized controlled trial
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
180 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06345937
Sponsor's protocol ID
REB #44724
Acronym
MsFIT
Status last verified
Sep 2025
First submitted
28 Mar 2024
Last updated
17 Sep 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Behavioural Experimental: guidelines-based physical activity, Behavioural Experimental: guidelines-based physical activity and healthy eating and Behavioural: Stretching exercise in people with Metabolic Disturbance and Sedentary Behavior, run by University of Toronto at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 17 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Amy A. Kirkham, PhD (416-946-4069, amy.kirkham@utoronto.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Insulin resistance (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2025; AzTrials last refreshed its copy on 27 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in